Limited coverage criteria – ustekinumab for psoriatic arthritis

Last updated on March 27, 2025

Special Authority requests can now be submitted online. It's simple and quick!

Generic name: ustekinumab
Brand name	Strength	Form
Jamteki™	45 mg/0.5 mL	pre-filled syringe
	90 mg/1 mL
Wezlana™	45 mg/0.5 mL	pre-filled syringe single-use vial
	90 mg/1 mL	pre-filled syringe
Steqeyma^®	45 mg/0.5 mL	pre-filled syringe
	90 mg/1 mL	pre-filled syringe

Special Authority criteria	Approval period
For the treatment of adult patients with active psoriatic arthritis (PsA) according to established criteria¹when a Special Authority request is submitted by a rheumatologist	Initial approval: 1 year Renewal: 1 year

Practitioner exemptions

None

Special notes

¹Established criteria are explained in the Special Authority forms below
PharmaCare coverage will not be provided for ustekinumab in combination with other biologic drugs or a janus kinase (JAK)-inhibitor for the treatment of PsA
PharmaCare covers a maximum 84-day supply per fill of ustekinumab

Special Authority request form(s)

Did you find what you were looking for?

The B.C. Public Service acknowledges the territories of First Nations around B.C. and is grateful to carry out our work on these lands. We acknowledge the rights, interests, priorities, and concerns of all Indigenous Peoples - First Nations, Métis, and Inuit - respecting and acknowledging their distinct cultures, histories, rights, laws, and governments.

More topics

Limited coverage criteria – ustekinumab for psoriatic arthritis

Generic name: ustekinumab

Brand name

Strength

Form

Special Authority criteria

Approval period

Practitioner exemptions

Special notes

Special Authority request form(s)